What are antibody-drug conjugates (ADCs) and how do they work

Understanding Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates are a sophisticated type of cancer treatment that combines two powerful components: a targeted antibody and a potent chemotherapy drug. Think of them as "guided missiles" that deliver cancer-killing medication directly to tumor cells.

How ADCs Work: The Three-Part System

PART 1 - THE TARGETING ANTIBODY: The antibody portion is designed to recognize and bind to specific proteins on cancer cell surfaces. These proteins (called antigens) are often overexpressed on tumor cells but present in lower amounts on healthy cells. Common targets include HER2, CD30, and TROP-2.

PART 2 - THE LINKER: A chemical linker connects the antibody to the drug. This linker is engineered to remain stable in the bloodstream but break apart once inside cancer cells, releasing the toxic payload only where it's needed.

PART 3 - THE CYTOTOXIC DRUG: The attached chemotherapy drug is typically much more potent than standard chemotherapy—often 100-1000 times stronger. Because it's delivered directly to cancer cells, lower doses can be used compared to traditional chemotherapy, potentially reducing side effects.

The Delivery Process

1. Circulation: The ADC travels through the bloodstream
2. Recognition: The antibody finds and attaches to target proteins on cancer cells
3. Internalization: The cancer cell pulls the entire ADC inside
4. Release: Inside the cell, the linker breaks down and releases the toxic drug
5. Cell Death: The chemotherapy drug damages the cancer cell's DNA, causing it to die

Clinical Advantages

According to NCCN Guidelines and ASCO recommendations, ADCs offer several benefits:

• Precision targeting reduces exposure of healthy cells to chemotherapy
• Potentially fewer side effects compared to traditional chemotherapy
• Effective against resistant cancers that may not respond to standard treatments
• FDA-approved options now exist for multiple cancer types

Examples of FDA-Approved ADCs

Several ADCs are now available for cancer treatment, including those targeting HER2-positive breast cancer, CD30-positive lymphomas, and TROP-2-positive cancers. Your oncologist can discuss which ADCs, if any, might be relevant to your specific cancer type and characteristics.

Questions to Ask Your Oncologist

If ADCs are being considered for your treatment:

1. Is an ADC appropriate for my specific cancer type and biomarkers?
2. What is the target protein, and why is my cancer a good match?
3. What are the expected side effects, and how do they compare to other options?
4. What is the typical treatment schedule and duration?
5. How will my response to the ADC be monitored?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.